Treatment for lung fibrosis caused by cancer therapy
Phase II Study of Bevasizumab in the Management of Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis
This study is testing if a new drug called Bevasizumab can help cancer patients with lung fibrosis caused by their treatment, compared to just using a standard medication.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Qingdao Central Hospital Academic / other |
| Drugs / interventions | Bevasizumab, chemotherapy, radiation |
| Locations | 1 site (Qingdao, Shandong) |
| Trial ID | NCT01917877 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of Bevasizumab, a VEGF inhibitor, in treating acute pulmonary fibrosis that occurs as a result of radiation and chemotherapy in cancer patients. Participants will be randomly assigned to receive either Bevasizumab combined with Dexamethasone or Dexamethasone alone. The study will assess various biomarkers and imaging results at multiple time points to evaluate the treatment's impact. The target sample size is 30 patients, focusing on those diagnosed with treatment-induced pulmonary fibrosis.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with acute pulmonary fibrosis resulting from cancer treatment.
Not a fit: Patients with chronic pulmonary fibrosis or those whose condition is due to infections will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the management of pulmonary fibrosis in cancer patients, enhancing their quality of life.
How similar studies have performed: While the approach using Bevasizumab for this specific condition is novel, similar studies targeting pulmonary complications have shown promise.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * clinical diagnosed cancer treatment-induced acute pulmonary fibrosis Exclusion Criteria: * chronic pulmonary fibrosis and infection-induced pulmonary fibrosis * active bleeding * uncontrolled high blood pressure * unstable systemic disease * prior exposure to VEGF inhibitor
Where this trial is running
Qingdao, Shandong
- Qingdao Central Hospital — Qingdao, Shandong, China (Recruiting)
Study contacts
- Principal investigator: youxin ji, md — Qingdao Central Hospital
- Study coordinator: youxin ji, md
- Email: ji6677@gmail.com
- Phone: 86532-68665078
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.